New Zealand markets closed

ESPR Jan 2026 2.500 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.94000.0000 (0.00%)
As of 11:06AM EDT. Market open.
Full screen
Previous close0.9400
Open0.9400
Bid0.0000
Ask0.0000
Strike2.50
Expiry date2026-01-16
Day's range0.9400 - 0.9400
Contract rangeN/A
Volume2
Open interestN/A
  • GlobeNewswire

    Esperion to Participate in Upcoming BTIG Biotech Conference

    ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion TherapeuticsAt Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that i

  • Zacks

    Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

    Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

  • GlobeNewswire

    New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries

    – Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls – – Recent FDA-Approved Label Expansion For NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Allows Esperion the Opportunity to Help Educate the More Than 70 Million Americans Currently Dealing With High LDL-C In The U.S. – ANN ARBOR, Mich., July 16